{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:19Z","timestamp":1791646459046,"version":"4.3.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ek0109567"],"award-info":[{"award-number":["JP21ek0109567"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Portopulmonary hypertension (PoPH) is a rare subtype of Group 1 pulmonary arterial hypertension (PAH) with a poor prognosis. According to the most up-to-date definition, PoPH is characterized by a mean pulmonary arterial pressure (PAP) of &amp;gt;20\u2009mmHg at rest, a pulmonary artery wedge pressure of \u226415\u2009mmHg, and a pulmonary vascular resistance (PVR) of &amp;gt;2 Wood units with portal hypertension. Like PAH, PoPH is underpinned by an imbalance in vasoactive substances. Therefore, current guidelines recommend PAH-specific therapies for PoPH treatment; however, descriptions of the actual treatment approaches are inconsistent. Given the small patient population, PoPH is often studied in combination with idiopathic PAH; however, recent evidence suggests important differences between PoPH and idiopathic PAH in terms of hemodynamic parameters, treatment approaches, survival, socioeconomic status, and healthcare utilization. Therefore, large, multi-center registry studies are needed to examine PoPH in isolation while obtaining statistically meaningful results. PoPH has conventionally been excluded from clinical drug trials because of concerns over hepatotoxicity. Nevertheless, newer-generation endothelin receptor antagonists have shown great promise in the treatment of PoPH, reducing PVR, PAP, and World Health Organization functional class without causing hepatotoxicity. The role of liver transplantation as a treatment option for PoPH has also been controversial; however, recent evidence shows that this procedure may be beneficial in this patient population. In the future, given the shortage of liver donors, predictors of a favorable response to liver transplantation should be determined to select the most eligible patients. Collectively, advances in these three areas could help to standardize PoPH treatment in the clinic.<\/jats:p>","DOI":"10.3389\/fmed.2023.1142836","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:27:28Z","timestamp":1680586048000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Current clinical understanding and effectiveness of portopulmonary hypertension treatment"],"prefix":"10.3389","volume":"10","author":[{"given":"Yuichi","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2466-14-45","article-title":"Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry","volume":"14","author":"Jansa","year":"2014","journal-title":"BMC Pulm Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1378\/chest.11-0160","article-title":"Portopulmonary hypertension: a report from the US-based REVEAL registry","volume":"141","author":"Krowka","year":"2012","journal-title":"Chest"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1253\/circrep.CR-22-0098","article-title":"Clinical management and outcomes of patients with portopulmonary hypertension enrolled in the Japanese multicenter registry","volume":"4","author":"Tamura","year":"2022","journal-title":"Circ Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/hepr.13560","article-title":"Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization","volume":"50","author":"Atsukawa","year":"2020","journal-title":"Hepatol Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/hep.22275","article-title":"Clinical risk factors for portopulmonary hypertension","volume":"48","author":"Kawut","year":"2008","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/hep.21431","article-title":"Portopulmonary hypertension: results from a 10-year screening algorithm","volume":"44","author":"Krowka","year":"2006","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"8252","DOI":"10.3748\/wjg.v19.i45.8252","article-title":"Management of portopulmonary hypertension: new perspectives","volume":"19","author":"Mancuso","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/hep.24422","article-title":"Idiopathic noncirrhotic portal hypertension","volume":"54","author":"Schouten","year":"2011","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.healun.2016.12.014","article-title":"Survival in portopulmonary hypertension: outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry","volume":"36","author":"Sithamparanathan","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12890-021-01452-3","article-title":"The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan","volume":"21","author":"Takahashi","year":"2021","journal-title":"BMC Pulm Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"569413","DOI":"10.3389\/fmed.2020.569413","article-title":"Portopulmonary hypertension: from bench to bedside","volume":"7","author":"Thomas","year":"2020","journal-title":"Front Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"9629570","DOI":"10.1155\/2018\/9629570","article-title":"Prevalence and prognosis of portopulmonary hypertension in 223 liver transplant recipients","volume":"2018","author":"Li","year":"2018","journal-title":"Can Respir J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1183\/09031936.04.00010904","article-title":"ERS task force pulmonary-hepatic vascular disorders (PHD) scientific committee. Pulmonary\u2013hepatic vascular disorders (PHD)","volume":"24","author":"Rodr\u00edguez-Roisin","year":"2004","journal-title":"Eur Respir J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/cld.78","article-title":"Approach to the diagnosis of portal hypertension","volume":"1","author":"Koh","year":"2012","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jhep.2011.07.005","article-title":"Non invasive evaluation of portal hypertension using transient elastography","volume":"56","author":"Castera","year":"2012","journal-title":"J Hepatol"},{"key":"ref22","unstructured":"RubinLJ\n            HopkinsW\n          2022"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamacardio.2016.4471","article-title":"Pulmonary arterial hypertension diagnosis, treatment, and clinical management in the contemporary era","volume":"1","author":"Maron","year":"2016","journal-title":"JAMA Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1802148","DOI":"10.1183\/13993003.02148-2018","article-title":"An overview of the 6th world symposium on pulmonary hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2200107","DOI":"10.1183\/13993003.00107-2022","article-title":"Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 wood units","volume":"60","author":"Certain","year":"2022","journal-title":"Eur Respir J"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.chest.2018.09.017","article-title":"Evidence for an association between intrahepatic vascular changes and the development of hepatopulmonary syndrome","volume":"155","author":"Lejealle","year":"2019","journal-title":"Chest"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/0003319710369101","article-title":"Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation","volume":"61","author":"Pellicelli","year":"2010","journal-title":"Angiology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/gut.52.9.1355","article-title":"Portopulmonary hypertension in decompensated cirrhosis with refractory ascites","volume":"52","author":"Benjaminov","year":"2003","journal-title":"Gut"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1034\/j.1600-0676.2001.021002114.x","article-title":"Enhanced expression of endothelin receptor subtypes in cirrhotic rat liver","volume":"21","author":"Yokomori","year":"2001","journal-title":"Liver"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1136\/gut.2005.088633","article-title":"Role of endothelin in systemic and portal resistance in cirrhosis","volume":"55","author":"Angus","year":"2006","journal-title":"Gut"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/lt.500060209","article-title":"A spectrum of pulmonary vascular pathology in portopulmonary hypertension","volume":"6","author":"Krowka","year":"2000","journal-title":"Liver Transpl"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/j.1440-1746.2005.03914.x","article-title":"Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome","volume":"20","author":"Sztrymf","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jhep.2012.01.019","article-title":"Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease","volume":"56","author":"Fouts","year":"2012","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1161\/CIRCULATIONAHA.122.059949","article-title":"Decoding the link between inflammation and pulmonary arterial hypertension","volume":"146","author":"Zhong","year":"2022","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/CIRCRESAHA.115.303404","article-title":"The genetics of pulmonary arterial hypertension","volume":"115","author":"Austin","year":"2014","journal-title":"Circ Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.3748\/wjg.v20.i10.2555","article-title":"Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis","volume":"20","author":"Bolognesi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/gut.52.9.1355","article-title":"Portopulmonary hypertension in decompensated cirrhosis with refractory ascited","volume":"52","author":"Benjaminov","year":"2003","journal-title":"Gut"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/0003319710369101","article-title":"Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthopedic liver transplantation","volume":"61","author":"Pellicelli","year":"2010","journal-title":"Angiology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1183\/09059180.00007211","article-title":"Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview","volume":"21","author":"Porres-Aguilar","year":"2012","journal-title":"Eur Respir Rev"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s12328-019-00956-0","article-title":"Vascular syndromes in liver cirrhosis","volume":"12","author":"Shenoda","year":"2019","journal-title":"Clin J Gastroenterol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"5595614","DOI":"10.1155\/2021\/5595614","article-title":"Prevalence and associated factors of portopulmonary hypertension in patients with portal hypertension: a case-control study","volume":"2021","author":"Shao","year":"2021","journal-title":"Biomed Res Int"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respir Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.healun.2019.12.008","article-title":"Ambrisentan in portopulmonary hypertension: a multicenter, open-label trial","volume":"39","author":"Preston","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jhep.2020.02.021","article-title":"Portopulmonary hypertension in the current era of pulmonary hypertension management","volume":"73","author":"Savale","year":"2020","journal-title":"J Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"20458940211020913","DOI":"10.1177\/20458940211020913","article-title":"Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association registry","volume":"11","author":"DuBrock","year":"2021","journal-title":"Pulm Circ"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/imj.14751","article-title":"Portopulmonary hypertension: prognosis and management in the current treatment era \u2013 results from the REHAP registry","volume":"51","author":"Salvador","year":"2021","journal-title":"Intern Med J"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/jgh3.12820","article-title":"Treatment pattern and clinical outcomes in portopulmonary hypertension: a database study in Japan","volume":"6","author":"Atsukawa","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1016\/j.mayocp.2021.05.026","article-title":"Topic-based, recent literature review on pulmonary hypertension","volume":"96","author":"Burger","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/2040622315590757","article-title":"Medical treatment update on pulmonary arterial hypertension","volume":"6","author":"Enderby","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/hep.31164","article-title":"Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis","volume":"72","author":"Deroo","year":"2020","journal-title":"Hepatology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1097\/TP.0000000000003490","article-title":"Clinical outcomes after liver transplantation in patients with portopulmonary hypertension","volume":"105","author":"Cartin-Ceba","year":"2021","journal-title":"Transplantation"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4097\/kjae.2018.71.2.85","article-title":"Cardiovascular dysfunction and liver transplantation","volume":"71","author":"Kwon","year":"2018","journal-title":"Korean J Anesthesiol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3748\/wjg.v22.i6.2024","article-title":"Portopulmonary hypertension in liver transplant candidates","volume":"22","author":"Bozbas","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.healun.2009.04.013","article-title":"Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition","volume":"28","author":"Botha","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/lt.26091","article-title":"Pulmonary vascular resistance predicts mortality and graft failure in transplantation patients with portopulmonary hypertension","volume":"27","author":"Jose","year":"2021","journal-title":"Liver Transpl"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1142836\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:27:35Z","timestamp":1680586055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1142836\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":58,"alternative-id":["10.3389\/fmed.2023.1142836"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1142836","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]},"article-number":"1142836"}}